Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
FDA red and green lights: February 2025
Adcetris bags its eighth approval, while SpringWorks and Ono also feature.
Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Will Roche's Perseverance pay off?
Giredestrant will soon become the first oral SERD to yield first-line data.
Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
Pivotal study designs revealed
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
